Diphyllobothriasis Treatment & Management
- Author: Derek Ryan Linklater, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD more...
Most patients with diphyllobothriasis, unless they have severe symptoms, can be safely treated as outpatients. Inpatient care is not generally required but may have to be considered in advanced, resistant, or complicated cases.
Diphyllobothriasis is treated by pharmacologic means; surgical treatment is not required unless otherwise indicated (eg, in a patient presenting with intestinal obstruction). Even in the face of decreased vitamin B-12 levels, less than 2% of patients with diphyllobothriasis develop anemia. Vitamin supplementation may be required in severe cases. As a rule, no activity limitations or restrictions are necessary.
Treatment of diphyllobothriasis is pharmacologic. Because the parasite’s biochemical pathways are different from those of the human host, drug toxicity is directed toward the parasite, the egg, or the larvae. Mechanisms of action vary within a drug class. Antiparasitic actions may include the following:
Inhibition of microtubules, causing irreversible block of glucose uptake
Tubulin polymerization inhibition
Depolarizing neuromuscular blockade
Increased cell membrane permeability, resulting in intracellular calcium loss
Vacuolization of the schistosome tegument
Increased cell membrane permeability to chloride ions via chloride channels alteration
Praziquantel is considered the drug of choice for D latum infection, with niclosamide as an alternative.
The neurologic and hematologic manifestations of vitamin B-12 deficiency respond well to supplementation. In the case of vitamin B-12 deficiency secondary to diphyllobothriasis, the signs and symptoms may resolve with antiparasitic therapy alone.
Resistant or advanced cases of diphyllobothriasis may require consultation with a gastroenterologist and an infectious disease specialist. Consultation with a hematologist may be considered, depending on the severity of anemia. In the case of suspected obstruction, consultation with a surgeon is indicated.
The patient’s stool should be reexamined on day 7 after therapy to test for cure. The presence of any Diphyllobothrium segments or ova in the stool on posttherapy day 7 constitutes a treatment failure. If the first course of treatment fails, a second identical course of therapy may be administered.
Arizono N, Shedko M, Yamada M, Uchikawa R, Tegoshi T, Takeda K, et al. Mitochondrial DNA divergence in populations of the tapeworm Diphyllobothrium nihonkaiense and its phylogenetic relationship with Diphyllobothrium klebanovskii. Parasitol Int. 2009 Mar. 58(1):22-8. [Medline].
Church C, Neill A, Schotthoefer AM. Intestinal infections in humans in the Rocky Mountain region, United States. J Parasitol. 2010 Feb. 96(1):194-6. [Medline].
Lee EB, Song JH, Park NS, et al. A case of Diphyllobothrium latum infection with a brief review of diphyllobothriasis in the Republic of Korea. Korean J Parasitol. 2007 Sep. 45(3):219-23. [Medline].
Lal S, Steinhart AH. Diphyllobothrium latum: a case of an incidental finding. World J Gastroenterol. 2007 Mar 28. 13(12):1875-6. [Medline].
Koontz F, Weinstock JV. The approach to stool examination for parasites. Gastroenterol Clin North Am. 1996 Sep. 25(3):435-49. [Medline].
Wicht B, Yanagida T, Scholz T, Ito A, Jiménez JA, Brabec J. Multiplex PCR for differential identification of broad tapeworms (Cestoda: Diphyllobothrium) infecting humans. J Clin Microbiol. 2010 Sep. 48(9):3111-6. [Medline]. [Full Text].
Hirata M, Yamaguchi Y, Ikei Y, et al. A case of Diphyllobothrium latum/nihonkaiense infection identified by capsule endoscopy in small intestine. Gastrointest Endosc. 2006 Jul. 64(1):129; discussion 130. [Medline].
Soga K, Sakagami J, Handa O, Konishi H, Wakabayashi N, Yagi N, et al. Long fish tapeworm in the intestine: an in situ observation by capsule endoscopy. Intern Med. 2011. 50(4):325-7. [Medline].
Craig P, Ito A. Intestinal cestodes. Curr Opin Infect Dis. 2007 Oct. 20(5):524-32. [Medline].